Novartis International AG

Novartis Launches $23 Billion North Carolina Manufacturing Hub

Novartis plans to establish a flagship manufacturing hub in North Carolina by 2027-2028 as part of a $23 billion investment in US infrastructure.

Novartis to Acquire Anthos Therapeutics

Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Novartis Acquires Kate Therapeutics for $1.1 Billion

Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.

Novartis and Versant Launch Borealis Biosciences

Novartis announced it has partnered with Versant Ventures to form Borealis Biosciences, an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases.

Novartis to Acquire Mariana Oncology

Swiss drugmaker Novartis agreed to acquire Mariana Oncology, a US biotechnology company based in Watertown, Massachusetts, that develops novel radioligand therapies (RLTs) for the treatment of cancer.

Novartis to Close US Generics Unit, Keep Roche Stake